MX2015013137A - Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso. - Google Patents

Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.

Info

Publication number
MX2015013137A
MX2015013137A MX2015013137A MX2015013137A MX2015013137A MX 2015013137 A MX2015013137 A MX 2015013137A MX 2015013137 A MX2015013137 A MX 2015013137A MX 2015013137 A MX2015013137 A MX 2015013137A MX 2015013137 A MX2015013137 A MX 2015013137A
Authority
MX
Mexico
Prior art keywords
subject
methods
same
breathing control
modulating compounds
Prior art date
Application number
MX2015013137A
Other languages
English (en)
Spanish (es)
Inventor
Scott Dax
Vita Ozola
Edgars Suna
James Joseph Mencel
Kirill Shubin
Marina Martjuga
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of MX2015013137A publication Critical patent/MX2015013137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Otolaryngology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2015013137A 2013-03-15 2014-03-13 Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso. MX2015013137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792185P 2013-03-15 2013-03-15
PCT/US2014/025792 WO2014151462A1 (en) 2013-03-15 2014-03-13 Novel breathing control modulating compounds, and methods of using same

Publications (1)

Publication Number Publication Date
MX2015013137A true MX2015013137A (es) 2016-05-05

Family

ID=51580966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013137A MX2015013137A (es) 2013-03-15 2014-03-13 Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.

Country Status (14)

Country Link
US (1) US9643971B2 (enExample)
EP (1) EP2968329A4 (enExample)
JP (1) JP2016516714A (enExample)
KR (1) KR20150143498A (enExample)
CN (1) CN105209041A (enExample)
AU (1) AU2014234095A1 (enExample)
BR (1) BR112015023671A2 (enExample)
CA (1) CA2905950A1 (enExample)
EA (1) EA201591693A1 (enExample)
HK (1) HK1219234A1 (enExample)
MX (1) MX2015013137A (enExample)
SG (1) SG11201507140PA (enExample)
WO (1) WO2014151462A1 (enExample)
ZA (1) ZA201507064B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102269311B1 (ko) 2013-07-05 2021-06-28 소니그룹주식회사 송신 장치, 송신 방법, 수신 장치 및 수신 방법
CA2989885C (en) * 2015-06-30 2025-05-06 Neurad Ltd. NEW RESPIRATION REGULATION MODULATION COMPOUNDS AND THEIR MANUFACTURING AND USE PROCESSES
US20210244742A1 (en) * 2015-07-22 2021-08-12 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
WO2021021236A1 (en) * 2019-07-26 2021-02-04 Heteron Biotechnologies, Llc Breath analyzer and urea breath test method
KR20260053367A (ko) * 2023-08-14 2026-04-21 뉴림 파머슈티칼스(1991) 리미티드 Gal475 조성물 및 그의 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
JPS557430B2 (enExample) 1972-05-17 1980-02-25
US4963541A (en) 1989-02-22 1990-10-16 Abbott Laboratories Pyrimido-pyrimidine lipoxygenase inhibiting compounds
US5075290A (en) 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5679650A (en) 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
SG10201601507YA (en) 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Also Published As

Publication number Publication date
WO2014151462A4 (en) 2014-11-13
CA2905950A1 (en) 2014-09-25
JP2016516714A (ja) 2016-06-09
EP2968329A1 (en) 2016-01-20
ZA201507064B (en) 2017-01-25
SG11201507140PA (en) 2015-10-29
BR112015023671A2 (pt) 2017-07-18
KR20150143498A (ko) 2015-12-23
CN105209041A (zh) 2015-12-30
US9643971B2 (en) 2017-05-09
WO2014151462A1 (en) 2014-09-25
US20160046635A1 (en) 2016-02-18
EA201591693A1 (ru) 2016-03-31
EP2968329A4 (en) 2016-09-28
AU2014234095A1 (en) 2015-10-08
HK1219234A1 (zh) 2017-03-31

Similar Documents

Publication Publication Date Title
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12015501531B1 (en) Crenolanib for treating flt3 mutated proliferative disorders
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
NZ630367A (en) Methods of treatment of pediatric solid tumor
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
EA032955B1 (ru) Применение производного глутаримида для лечения эозинофильных заболеваний
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MY189342A (en) Treatment and prevention of the common cold using povidone-iodine
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201591693A1 (ru) Новые соединения, модулирующие контроль над дыханием, и способы их применения
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MY196333A (en) Intranasal Composition Comprising Betahistine
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
MX2015001677A (es) Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion.